1. Home
  2. XGN vs MXCT Comparison

XGN vs MXCT Comparison

Compare XGN & MXCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Exagen Inc.

XGN

Exagen Inc.

HOLD

Current Price

$3.59

Market Cap

80.5M

Sector

Health Care

ML Signal

HOLD

Logo MaxCyte Inc.

MXCT

MaxCyte Inc.

HOLD

Current Price

$0.77

Market Cap

86.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
XGN
MXCT
Founded
2002
1999
Country
United States
United States
Employees
N/A
N/A
Industry
Medical Specialities
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
80.5M
86.5M
IPO Year
2014
2021

Fundamental Metrics

Financial Performance
Metric
XGN
MXCT
Price
$3.59
$0.77
Analyst Decision
Strong Buy
Buy
Analyst Count
7
4
Target Price
$11.00
$7.50
AVG Volume (30 Days)
354.2K
1.4M
Earning Date
04-06-2026
04-06-2026
Dividend Yield
N/A
N/A
EPS Growth
38.06
N/A
EPS
N/A
N/A
Revenue
N/A
$38,627,000.00
Revenue This Year
$20.99
N/A
Revenue Next Year
$11.27
$9.64
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.80
$0.64
52 Week High
$12.23
$3.58

Technical Indicators

Market Signals
Indicator
XGN
MXCT
Relative Strength Index (RSI) 42.42 34.39
Support Level $3.15 $0.75
Resistance Level $4.00 $1.82
Average True Range (ATR) 0.27 0.06
MACD 0.11 0.03
Stochastic Oscillator 55.29 67.33

Price Performance

Historical Comparison
XGN
MXCT

About XGN Exagen Inc.

Exagen Inc is a commercial-stage diagnostics company committed to addressing the unmet need for the accurate diagnosis and monitoring of patients affected by autoimmune rheumatic diseases. It currently markets ten testing products under its Avise brand to provide an accurate, timely, and differential diagnosis and to optimize the treatment of ARDs. It markets and sells solutions to community rheumatologists.

About MXCT MaxCyte Inc.

MaxCyte Inc is a commercial cell engineering company focused on providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics and to support cell-based research and development. The company has developed and commercialized a proprietary Flow Electroporation platform, which facilitates the complex engineering of a wide variety of cells. The Company has one reportable segment, cell engineering technology. The revenue is generated from the sale and licensing of company's instruments, as well as sales of single-use disposable processing assemblies.

Share on Social Networks: